Four new ZonMw awards highlight the strength of the academic drug discovery ecosystem on the VU campus, where medicinal chemists of the Amsterdam Institute of Molecular and Life Sciences (AIMMS) are increasingly joining forces with colleagues from the VU’s Center for Neurogenomics and Cognitive Research (CNCR) and Amsterdam UMC neuroscientists to accelerate the development of new Alzheimer’s therapies.
A key factor underlying this success is the strong cross-disciplinary collaboration across the VU Amsterdam campus. Although the projects target different aspects of Alzheimer’s disease, the principal investigators are closely connected, regularly exchange expertise, and actively support each other’s projects. This collaborative network fosters synergy between complementary approaches, accelerating scientific progress while strengthening the translation of discoveries into meaningful treatments for patients.
Within this collaborative framework, the funded projects address several complementary therapeutic strategies.
The awarded projects include:
What makes this achievement particularly is the strong, cross-discipline collaboration between researchers across disciplines and institutions on the VU Amsterdam campus. Despite working on different aspects of Alzheimer’s disease, the principal investigators are closely connected, regularly exchange expertise, and actively support each other’s projects. This integrated approach not only accelerates scientific progress but also increases the likelihood that promising discoveries will translate into meaningful treatments for patients.



